In today’s session Qiagen NV (QGEN) registered an unusually high (186) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the February, 2017 call, expecting serious QGEN increase. With 186 contracts traded and 9584 open interest for the Feb, 17 contract, it seems this is a quite bullish bet. The option with symbol: QGEN170217C00030000 closed last at: $0.75 or 114.3% up. About 528,862 shares traded hands. Qiagen NV (NASDAQ:QGEN) has risen 20.96% since April 5, 2016 and is uptrending. It has outperformed by 19.01% the S&P500.
Qiagen NV (NASDAQ:QGEN) Ratings Coverage
Out of 10 analysts covering Qiagen (NASDAQ:QGEN), 4 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 40% are positive. $33 is the highest target while $20 is the lowest. The $26.80 average target is -1.83% below today’s ($27.3) stock price. Qiagen has been the topic of 14 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Bank of America upgraded the shares of QGEN in a report on Thursday, November 3 to “Neutral” rating. The stock has “Overweight” rating given by Morgan Stanley on Tuesday, September 15. The firm has “Neutral” rating given on Thursday, July 30 by Mizuho. The stock has “Neutral” rating given by Citigroup on Tuesday, March 15. On Thursday, July 30 the stock rating was maintained by Barclays Capital with “Overweight”. The firm has “Hold” rating given on Thursday, November 12 by Stifel Nicolaus.
According to Zacks Investment Research, “Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.”
QIAGEN N.V. is a holding company. The company has a market cap of $6.42 billion. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. It has a 54.67 P/E ratio. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
QGEN Company Profile
QIAGEN N.V. (QIAGEN), incorporated on April 29, 1996, is a holding company. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. The Company’s solutions support over 500,000 clients across the world in generating insights into the molecular building blocks of life. The Company’s over two billion biological samples have been prepared or analyzed using QIAGEN sample technologies. The Company’s sample technologies are used in isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. The Company’s assay technologies make these biomolecules visible for analysis, such as identifying the DNA of a virus or a gene mutation in a tumor. The Company’s bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms tie these together in molecular testing workflows – from Sample to Insight. The Company’s Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to decide on further action. The Firm offers solutions in molecular diagnostics, applied testing, pharma and academia.
More news for Qiagen NV (NASDAQ:QGEN) were recently published by: Prnewswire.com, which released: “QIAGEN N.V. to Report Third Quarter and First Nine Months of 2016 Results” on October 11, 2016. Rttnews.com‘s article titled: “Qiagen NV Announces 8% Rise In Q3 Profit” and published on November 02, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.